iGlarLixi治疗2型糖尿病的患者报告结局综述
本综述汇总iGlarLixi在2型糖尿病成人患者中的患者报告结局（PROs）数据，涵盖Soli-CGM、SoliMix、Soli-SWITCH、IDEAL、SUCCESS和SIMPLIFY JP等研究。结果显示，每日一次iGlarLixi在从复杂胰岛素方案、基础胰岛素或口服降糖药转换的患者中，与治疗满意度和生活质量指标的数值改善相关。
要点
- 每日一次iGlarLixi可简化复杂胰岛素方案，患者报告的治疗满意度有数值改善。
- 真实世界研究中iGlarLixi与治疗满意度和生活质量改善相关。
- iGlarLixi相比复杂胰岛素方案有体重优势和较低低血糖风险。
核心结论
- 每日一次iGlarLixi可能为2型糖尿病成人患者提供临床有益且简化的治疗选择，优于复杂胰岛素方案。
研究设计与样本
- 这是首篇汇总多项iGlarLixi研究中多种经验证PRO量表的叙述性综述。
- 纳入研究包括Soli-CGM、SoliMix、Soli-SWITCH、IDEAL、SUCCESS和SIMPLIFY JP。
- 使用的PRO量表包括Global Treatment Effectiveness Evaluation、Audit of Diabetes Dependent Quality of Life、Diabetes Medication Satisfaction Tool、Diabetes Therapy-Related Quality of Life、Diabetes Treatment Satisfaction Questionnaire、Hypoglycaemic Attitudes and Behaviour Scale和Treatment-Related Impact Measure Diabetes。
主要发现
- 临床研究中，从复杂胰岛素方案、基础胰岛素或口服降糖药转换为每日一次iGlarLixi的患者，所选治疗满意度指标有数值改善。
- 真实世界研究中，既往接受基础-餐时胰岛素或口服降糖药±基础胰岛素或GLP-1 RA的2型糖尿病成人患者，iGlarLixi通常与治疗满意度和生活质量改善相关。
临床怎么用
- 对于使用复杂胰岛素方案或口服降糖药±基础胰岛素/GLP-1 RA控制不佳的2型糖尿病成人患者，可考虑转换为每日一次iGlarLixi以简化治疗并改善患者报告结局。
以上解读依据论文摘要（全文未开放获取或许可不允许翻译转载）。
原文
ABSTRACT Introduction Given the significant burden that diabetes self-management poses, it is important to assess patient-reported outcomes (PROs) for Type 2 diabetes (T2D) treatments in clinical trials and real-world studies. Complex insulin regimens are associated with increased risk of hypoglycaemia and body weight gain, which could negatively impact treatment adherence and, therefore, achievement of glycaemic targets. iGlarLixi is a once-daily fixed-ratio combination of insulin glargine 100 U/mL and the glucagon-like peptide-1 receptor agonist (GLP-1 RA), lixisenatide. iGlarLixi is an effective treatment alternative to complex insulin regimens, with a favourable between-group difference in body weight and reduced risk of hypoglycaemia. Methods This is the first review to summarise data from multiple validated PRO measures for recent iGlarLixi studies (Soli-CGM, SoliMix, Soli-SWITCH, IDEAL, SUCCESS and SIMPLIFY JP), including: Global Treatment Effectiveness Evaluation, Audit of Diabetes Dependent Quality of Life, Diabetes Medication Satisfaction Tool, Diabetes Therapy-Related Quality of Life, Diabetes Treatment Satisfaction Questionnaire, Hypoglycaemic Attitudes and Behaviour Scale and Treatment-Related Impact Measure Diabetes. Results In clinical studies, once-daily iGlarLixi was associated with numerical improvements in selected treatment satisfaction measures in those who switched from: complex insulin regimens (once- or twice-daily premixed insulin and basal-bolus insulin), basal insulin or oral glucose-lowering medications. Additionally, in real-world studies, iGlarLixi was generally associated with improvements in treatment satisfaction and quality of life outcomes in adults with T2D who previously received basal-bolus insulin or oral glucose-lowering medications ± basal insulin or GLP-1 RAs. Conclusions In conclusion, a once-daily injection of iGlarLixi may offer a clinically beneficial, simplified treatment option for adults with T2D compared with complex insulin-based regimens.
引用
- Diabetes, Obesity and Metabolism：Patient‐Reported Outcomes Following Initiation or Simplification of Treatment With iGlarLixi in Adults With Type 2 Diabetes: A Narrative Review
供执业医师工作参考，不替代临床判断；数值与分级以指南原文为准。